EE55 Cost-Effectiveness of ESMO-Recommended Lenvatinib and Pembrolizumab Regimen as Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: A Comparison With NCCN Recommendations
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.328
https://www.valueinhealthjournal.com/article/S1098-3015(23)03458-7/fulltext
Title :
EE55 Cost-Effectiveness of ESMO-Recommended Lenvatinib and Pembrolizumab Regimen as Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: A Comparison With NCCN Recommendations
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03458-7&doi=10.1016/j.jval.2023.09.328
First page :
Section Title :
Open access? :
No
Section Order :
12351